verapamil has been researched along with rivaroxaban in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Washam, JB | 1 |
| Chow, CR; Greenblatt, DJ; Harmatz, JS; Nicholson, WT; Patel, M; Rubino, CM | 1 |
| Chow, CR; Ismail, M; Lee, VH; Rubino, CM | 1 |
| Chan, ECY; Cheong, EJY; Chua, DXY; Teo, DWX | 1 |
| Bin, V; Delavenne, X; Delézay, O; He, Z; Hodin, S; Jacqueroux, E; Saib, S | 1 |
| Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D | 1 |
| Cui, C; Lai, X; Li, H; Liu, D; Sia, JEV; Wu, X; Zhang, F | 1 |
3 trial(s) available for verapamil and rivaroxaban
| Article | Year |
|---|---|
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Verapamil; Warfarin | 2017 |
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Topics: Adult; Aged; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Verapamil | 2018 |
Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.
Topics: Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Models, Biological; Renal Insufficiency; Risk; Rivaroxaban; Verapamil | 2018 |
5 other study(ies) available for verapamil and rivaroxaban
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Computer Simulation; Drug Interactions; Humans; Ketoconazole; Kidney; Models, Biological; Organic Anion Transporters, Sodium-Independent; Rivaroxaban; Verapamil | 2019 |
Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Caco-2 Cells; Chromatography, Liquid; Diketopiperazines; Dogs; Drug Interactions; Factor Xa Inhibitors; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neoplasm Proteins; Rivaroxaban; Tandem Mass Spectrometry; Verapamil | 2020 |
Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
Topics: Aged, 80 and over; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Cross-Sectional Studies; Drug Interactions; Female; Humans; Male; Rivaroxaban; Verapamil | 2020 |
Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
Topics: Administration, Oral; Aged; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; China; Clarithromycin; Dabigatran; Drug Interactions; East Asian People; Humans; Rivaroxaban; Verapamil | 2023 |